In October 2018, HHS Secretary Alex Azar proposed requiring drug companies to include the list price of a drug paid for by Medicare or Medicaid in direct-to-consumer (DTC) television advertising. Since the rule was announced, it has drawn feedback from stakeholders across the spectrum. The proposal, for which a comment period recently closed, received more than 140 comments on the Federal Register from payers, providers, patient advocacy groups, and others, varying in support of the proposal to raising concerns.
In October 2018, HHS Secretary Alex Azar proposed requiring drug companies to include the list price of a drug paid for by Medicare or Medicaid in direct-to-consumer (DTC) television advertising. Since the rule was announced, it has drawn feedback from stakeholders across the spectrum.
The proposal, for which a comment period recently closed, received more than 140 comments on the Federal Register from payers, providers, patient advocacy groups, and others, varying in support of the proposal to raising concerns.
Voicing support in its submitted comments, America’s Health Insurance Plans (AHIP) explained that, while drugmakers are responsible for the creation of life-saving treatment and breakthrough cures, “too many Americans must choose between paying for their bills and paying for their medications.” For this reason, AHIP supports “bold action” in order to increase access to affordable medications.
AHIP says it “strongly support[s] the disclosure of list prices for brand name drugs and biologics in direct-to-consumer drug advertisements,” and also encourages CMS to consider making compliance with this rule a condition of payment or participation in government health programs such as Medicare or Medicaid.
CVS Health also voiced support of the DTC proposal, saying that pharmaceutical manufacturers spent over $5.2 billion in 2015 on DTC television advertisements, though these ads contained no pricing information for patients or providers. Enacting the proposal “would put important information in the hands of the ultimate consumer: the patient.” Furthermore, CVS Health also supports expanding the pricing disclosures to other forms of media, including print, radio, online advertising, and social media.
The American Medical Association (AMA) echoed CVS Health, stating that it supports requiring pharmaceutical companies to disclose list prices in all advertisements. However, AMA noted that it is concerned that the proposal did not include a “valid enforcement mechanism,” and urges CMS to consider additional enforcement tools to compel compliance.
A number of groups submitted comments largely opposed to enactment of the proposal, however. The Global Healthy Living Foundation (GHLF), a patient advocacy organization that represents chronically ill patients and their caregivers, stated that it “firmly believe[s] that the success of any efforts to reduce drug prices should be measured by the reduction of financial burden on the patients.” Although GHLF supports greater transparency within the US healthcare system, it is concerned that the proposal would do “more harm than good by creating confusion for patients and doing little to lower their out-of-pocket costs.”
Additionally, while the Biotechnology Innovation Organization (BIO) states that it supports providing patients with more clarity about how medicines and other healthcare services are priced, “we believe CMS’ proposed approach—publishing a medicine’s Wholesale Acquisition Cost (WAC) with very minimal contextual information during a brief televised drug advertisement that commonly features the medicines profile, uses, and safety information—does not achieve this goal.” BIO is concerned that, instead of helping patients, the proposal will confuse consumers and potentially cause them to not seek necessary medical care due to “sticker shock” from the price.
Finally, one of the most vocal opponents of the proposed rule is the Pharmaceutical Research and Manufacturers of America (PhRMA). PhRMA emphasized that any cost-related information provided to patients should “actually help patients make informed decisions about their medical care.” In order to accomplish this goal, PhRMA announced that it launched a new platform that will “provide patients, caregivers, and providers with cost and financial assistance information for brand-name medicines, as well as other patient support resources.” The platform will take effect in April 2019, when signatory companies will include “direction as to where patients can find information about the cost of the medicine” in their respective DTC advertisements.
PhRMA also explained that CMS’ proposed rule raises legal concerns. “PhRMA does not believe that CMS has authority to issue the proposed rule under existing law and the separation of powers doctrine.” The organization went on to discuss the various First Amendment concerns it foresees with enactment of the proposal, and has strongly urged CMS to withdraw the proposed rule.
For his part, when announcing the proposal, Azar was firm that HHS will take action. “When we change the rules, the market players will reorganize their businesses to fit the new world. And it will be a very different world for American drug pricing.”
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.